SANTHERA AND TAKEDA ESTABLISH COLLABORATION TO DEVELOP AND MARKET IDEBENONE (SNT-MC17)

Santhera Pharmaceuticals AG ("Santhera") of Switzerland and Takeda Pharmaceutical Company Limited ("Takeda") of Japan announced today that they will collaborate to develop and commercialize Idebenone (SNT-MC17), a small molecule drug for the treatment of Friedreich's Ataxia ("FRDA"). The clinical development for FRDA is about to enter a Phase III clinical study in Europe and will enter a Phase III study in the US shortly thereafter. The product has orphan drug designation in the US and Europe.

PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=261569)